Skewed birth ratios raise fears of social crisis in Vietnam
By AsiaNews/Agencies,
AsiaNews/Agencies
| 07. 10. 2008
Vietnam could experience a major social crisis as a result of a skewed birth rate. Traditionally and for historical reasons Vietnamese women have been more numerous than men but in the last few years this trend has been reversed causing dangerous changes whose consequences can now be seen in countries like China and India.
The General Statistics Office of Vietnam sounded the alarm bell in a recently released study that indicated that "in 2007 the male-to-female ratio at birth was 112 to 100," up from 110 to 100 a year before and much higher than the average world sex ratio which stands at about 103-105 to 100. The study also showed that the skewed sex ratio is higher in some areas of the country, most notably in the north-west mountain regions.
One basic reason for this trend is the traditional preference for boys which has been aggravated by the possibility now available for sex selection.
Contraception and targeted pregnancies allow parents to have baby boys and abort the foetus if it is that of a baby girl.
If left unchecked...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...